Cargando…

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells

Here, we show that new mitochondrial biogenesis is required for the anchorage independent survival and propagation of cancer stem-like cells (CSCs). More specifically, we used the drug XCT790 as an investigational tool, as it functions as a specific inhibitor of the ERRα-PGC1 signaling pathway, whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Arianna, Fiorillo, Marco, Peiris-Pagès, Maria, Ozsvari, Bela, Smith, Duncan L., Sanchez-Alvarez, Rosa, Martinez-Outschoorn, Ubaldo E., Cappello, Anna Rita, Pezzi, Vincenzo, Lisanti, Michael P., Sotgia, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558115/ https://www.ncbi.nlm.nih.gov/pubmed/26087310

Ejemplares similares

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
por: Lamb, Rebecca, et al.
Publicado: (2015)

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”
por: Fiorillo, Marco, et al.
Publicado: (2015)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
por: Lamb, Rebecca, et al.
Publicado: (2015)

Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling
por: Lamb, Rebecca, et al.
Publicado: (2015)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)

Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction
por: Lamb, Rebecca, et al.
Publicado: (2015)

Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
por: Farnie, Gillian, et al.
Publicado: (2015)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

Cancer stem cell metabolism
por: Peiris-Pagès, Maria, et al.
Publicado: (2016)

Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
por: Lamb, Rebecca, et al.
Publicado: (2014)

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2016)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
por: Lamb, Rebecca, et al.
Publicado: (2015)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts
por: Ozsvari, Bela, et al.
Publicado: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells
por: Fiorillo, Marco, et al.
Publicado: (2016)

Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?
por: Sotgia, Federica, et al.
Publicado: (2011)

Genetic Induction of the Warburg Effect Inhibits Tumor Growth
por: Sotgia, Federica, et al.
Publicado: (2012)

Cancer Metabolism: New Validated Targets for Drug Discovery
por: Sotgia, Federica, et al.
Publicado: (2013)

The reverse warburg effect in osteosarcoma
por: Sotgia, Federica, et al.
Publicado: (2014)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
por: Ózsvári, Béla, et al.
Publicado: (2020)

Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway
por: Brindisi, Matteo, et al.
Publicado: (2020)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC)
por: Casaburi, Ivan, et al.
Publicado: (2015)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway
por: Tyagi, Ethika, et al.
Publicado: (2017)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fui4di9hp4eul2s5n3thgjepv6